Precipio in Strategic Partnership Discussions for Proprietary Cytogenetics Media IV-Cell

Specialty diagnostics company Precipio (NASDAQ:PRPO), announced today it is in active licensing discussions with several potential partners regarding IV-Cell, Precipio’s proprietary cytogenetics media.

As quoted in the press release:

Cytogenetics media is used to culture cells to mimic development of malignant cells in the body, and identify chromosomal abnormalities that may be causing cancer. This process helps the diagnostician identify abnormalities within the patient’s cells, in order to determine both the diagnosis (type) and prognosis (severity) of the disease.

IV-Cell provides two substantial improvements over current media used in the market.

First, it enables laboratory technicians to culture multiple cell lineages simultaneously, compared to existing media requiring upfront selection of a single target cell lineage which, once made cannot be changed. If the wrong cell lineage was selected, this could result in a mistaken diagnosis. Precipio’s internal data indicates that the potential selection of the incorrect cell lineage (based on the clinical indication submitted) can occur in up to 30% of cases.

Click here to read the full press release.